Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EMA’s Revised ATMP Evaluation Procedure Gets Industry Thumbs Up

Executive Summary

EU pharmaceutical companies believe the revisions the European Medicines Agency has made to its procedure for evaluating gene and cell therapy products addresses the specific needs of advanced therapy developers. They have also welcomed, in principle, a revised EMA guideline on the follow-up and risk management of such products.

You may also be interested in...



Industry Welcomes EU Action Plan To Boost ATMP Development

An action plan produced by the European Medicines Agency and the European Commission has put forward a number of ideas for streamlining the processes for developing and assessing advanced therapy medicines, with the aim of speeding up the current sluggish rate of ATMP approvals. Industry says it will assess the proposals to see how well they address the key issues worrying the sector.

EMA Aims For Better Info On Benefit-Risk Balance To Support Drug Choices In Pregnancy

The European Medicines Agency is developing a strategy to ensure that women have sufficient information to make informed choices about taking medicines during pregnancy and breastfeeding.

Study Shows RWD Can Replace Placebo Data In Duchenne Trials

A first-of-its-kind collaborative study has found that real-world and natural history data are comparable to placebo data from clinical trials in Duchenne muscular dystrophy.

Topics

UsernamePublicRestriction

Register

ID1132028

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel